Linked Life Data

10980871

Source:http://linkedlifedata.com/resource/pubmed/id/10980871

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2000-11-21
pubmed:abstractText
Several phase I/II clinical trials are currently ongoing in gene therapy of cardiovascular disease. Whereas the indications vary, including peripheral artery disease, ischemic heart disease, post-angioplasty restenosis, and vein graft failure, these trials are mostly based on the use of adenoviral vectors and nonviral vectors. Novel vectors aimed at improving the efficacy and safety of gene delivery in target organs, such as heart, skeletal muscle, vasculature, and liver, have been recently generated. Some of them have already been successfully validated in preclinical models of cardiovascular disease. This review focuses on the most recent advances in vector development that could substantially increase the spectrum of cardiovascular pathologies amenable to gene transfer-based treatments.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1523-3782
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
39-47
pubmed:dateRevised
2006-5-1
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Vectors for gene therapy of cardiovascular disease.
pubmed:affiliation
Vector Development Department, Rhône-Poulenc Rorer Gencell, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France.
pubmed:publicationType
Journal Article, Review